Ipsen media releases

Key highlights

Ipsen delivers robust sales growth in the first quarter of 2023 and confirms its full-year guidance

– 27 April 2023 – 1 mins read

27 April 2023 – 1 mins read

Ipsen delivers robust sales growth in the first quarter of 2023 and confirms its full-year guidance

Paris (France), 27 April 2023

Filter

Topics

Period

Filter by

Reset

Showing: 1 – 05 of 30 Press Releases

Show

Sort

Ipsen receives CHMP negative opinion for palovarotene as a treatment for fibrodysplasia ossificans progressiva in E.U.

– 27 January 2023

27 January 2023

Ipsen receives CHMP negative opinion for palovarotene as a treatment for fibrodysplasia ossificans progressiva in E.U.

PARIS, FRANCE, 27 January 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended not to grant marketing authorization for investi

Ipsen presents Phase III NAPOLI 3 trial of Onivyde® regimen demonstrating positive survival results in previously untreated metastatic pancreatic ductal adenocarcinoma at ASCO GI

– 20 January 2023

20 January 2023

Ipsen presents Phase III NAPOLI 3 trial of Onivyde® regimen demonstrating positive survival results in previously untreated metastatic pancreatic ductal adenocarcinoma at ASCO GI

PARIS, FRANCE, January 20, 2023, Ipsen (Euronext: IPN; ADR: IPSEY) today presented positive results from the pivotal Phase III NAPOLI 3 trial evaluating an investigational regimen of Onivyde® (irinotecan liposome injection), a long-circulating,

Ipsen to acquire Albireo accelerating growth in rare disease with treatments for several pediatric liver diseases

– 09 January 2023

09 January 2023

Ipsen to acquire Albireo accelerating growth in rare disease with treatments for several pediatric liver diseases

PARIS, FRANCE & BOSTON, U.S., 09 January 2023 – Ipsen (Euronext: IPN: ADR: IPSEY) and Albireo (Nasdaq: ALBO) today announced that they have entered into a definitive merger agreement under which Ipsen will acquire Albireo, a leading innovator in

Ipsen receives Complete Response Letter for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva

– 23 December 2022

23 December 2022

Ipsen receives Complete Response Letter for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva

PARIS, FRANCE, 23 December 2022 – The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the New Drug Application for palovarotene, an investigational treatment for the reduction of new abnormal bone formation

Ipsen provides update on Phase III CONTACT-01 trial evaluating cabozantinib in combination with atezolizumab in patients with metastatic non-small cell lung cancer previously treated with immunotherapy and chemotherapy

– 08 December 2022

08 December 2022

Ipsen provides update on Phase III CONTACT-01 trial evaluating cabozantinib in combination with atezolizumab in patients with metastatic non-small cell lung cancer previously treated with immunotherapy and chemotherapy

PARIS, FRANCE, 8 December 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the CONTACT-01 study did not meet its primary endpoint of overall survival (OS) at the final analysis. CONTACT-01 is a phase III clinical trial evaluating Cabome

1 2 3 4 5 6

Your dedicated contacts

Amy Wolf

Vice President, Corporate Brand Strategy and Communications

Ioana Piscociu

Senior Manager, Media Relations

Press Releases